Results Healthcare has advised Recipharm on the divestment of their API site in Cramlington, UK, to Pharmaron

Results Healthcare is delighted to announce that it has advised Recipharm, a top five global pharmaceutical CDMO, on the divestment of the Aesica Pharmaceuticals API manufacturing site located in Cramlington, UK, to Pharmaron.

This transaction highlights Results Healthcare’s excellent reputation in the healthcare and life sciences sector and is a testament to our international network. It highlights our deep sector expertise, strong buyer relationships, and outstanding track record of achieving high-value outcomes for our clients.

Recipharm is a world leading CDMO in the pharmaceutical industry, employing almost 9,000 employees across 30+ facilities in 10 countries. It offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and Active Pharmaceutical Ingredients (APIs), pharmaceutical product development as well as development and manufacturing of medical devices. The Aesica Pharmaceuticals Cramlington site near Newcastle, UK, has an established history of cGMP manufacturing services for an array of APIs. The divestment helps Recipharm streamline their operations in line with its ongoing strategy.

Pharmaron has acquired the Cramlington site to further expand its chemistry and manufacturing services and strengthen its global service network. The synergistic integration of the Cramlington site with Pharmaron’s existing service capabilities of discovery, process development and early-stage cGMP API manufacturing at Hoddesdon, will enable a complete end-to-end chemistry and manufacturing service offering in the United Kingdom.

Results Healthcare, with a team led by Kunal Kadiwar, Regina Gabitova, Bethany kersee, and Kevin Bttomley, served as financial adviser to Recipharm.